Jinan Meigao Biopharmaceutical Technology Co., Ltd.
Wy-14,643 (Pirinixic acid) is a moderate agonist of PPARα and PPARγ with IC50 of 36.5 μM and 53.7 μM, respectively. IC50 value: 36.5 μM (for PPARα), 53.7 μM (for PPARγ)  Target: PPARα, PPARγ in vitro: Wy-14,643 is a moderate agonist of PPARα and PPARγ, leads to low micromolar active balanced dual agonists of PPARα and PPARγ. The aliphatic substitution in α-position of the carboxylic acid head group of Wy-14,643 leads to more potent dual PPARα/γ agonists with a significant preference towards PPARα. Wy-14,643 exhibits beneficial effects in various inflammation-related processes in a slow, long-termed fashion.  in vivo: Wy-14,643 shows beneficial effects in animal models of inflammation and cardiovascular diseases that rely on slow-acting transcriptional events modulating protein expression. Wy-14,643 reduces the expression and production of cytokines, adhesion molecules, inducible NO synthase, heme oxygenase-1, and cyclooxygenase-2. Wy-14,643 inhibits human aldose reductase activity and increased uncoupling of oxidative phosphorylation in isolated mitochondria.
Copyright © 2018 Jinan Meigao Biopharmaceutical Technology Co., Ltd. All rights reserved.